← SearchTARGETING THE G2/M CHECKPOINT IN GLIOBLASTOMA WITH A COMBINED LOSS OF TP53 AND CDKN2A$264,750FY2019Department of the ArmyDODDana-Farber Cancer Institute, Inc.InvestigatorsView source on USAspending →